Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22151961 | 0.79 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23374135 | 0.79 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1070651 | 0.73 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14870536 | 0.73 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8697841 | 0.72 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7255368 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL31529612 | 0.70 | CHRNB2 (0.46) | CHRNB2CHRNA4RIPK1 | |
| SCHEMBL4294175 | 0.68 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5941207 | 0.68 | — | — | |
| SCHEMBL11628802 | 0.67 | CHRNA7 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110269040-A | A kind of method for building up of particulate matter breath exposure neurotoxicity rat model | 军事科学院军事医学研究院环境医学与作业医学研究所 | 2019-09-24 | — | — | CN | disclosed |
| US-20120183542-A1 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. | 2012-07-19 | — | — | US | disclosed |
| US-20090124993-A1 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1859277-A2 | TREATING NEUROLOGICAL DISORDERS | Biogen Idec MA Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070111932-A1 | Method of enhancing and/or inducing neuronal migration using erythropoietin | STEM CELL THERAPEUTICS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070100001-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20060234912-A1 | Methods for modulating neuronal responses | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-10-19 | — | — | US | disclosed |
| WO-2006089095-A2 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060094783-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | TAVA PHARMACEUTICAL INDUSTRIES, LTD. | 2006-05-04 | — | — | US | disclosed |
| US-6956060-B2 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-10-18 | — | — | US | disclosed |
| US-5891923-A | COGNITION ACTIVATORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-04-06 | — | — | US | disclosed |
| EP-0828485-A4 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1998-12-02 | — | — | EP | disclosed |
| CN-1191481-A | R-enantiomer of N-propargyl-1-aminoindan, salts thereof and use of compositions | TEVA PHARMA (IL) | 1998-08-26 | — | — | CN | disclosed |
| US-5786390-A | ENZYME INHIBITORS OF ENZYME MONOAMINE OXIDASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1998-07-28 | — | — | US | disclosed |
| US-5744500-A | ADMINISTERING TO TREAT BRAIN ISCHEMIA OR STROKE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-04-28 | — | — | US | disclosed |
| EP-0828485-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | Teva Pharmaceutical Industries, Inc. (IL) | 1998-03-18 | — | — | EP | disclosed |
| US-5599991-A | PARKINSON*S DISEASE; PSYCHOLOGICAL DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 1997-02-04 | — | — | US | disclosed |
| WO-1996037199-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-11-28 | — | — | WO | disclosed |
| US-5532415-A | MONOAMINE OXIDASE INHIBITORS; PARKINSON'S DISEASE, NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-07-02 | — | — | US | disclosed |
| US-5519061-A | MONOAMINE OXIDASE INHIBITORS, PARKINSON'S DISEASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094783-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | PNMT, DRD3, SNCA | CHRNB2 94/4885CHRNA4 80/4885CHRNB4 96/4885 |
| US-20070100001-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | PNMT, DRD3, SNCA | CHRNB2 94/4885CHRNA4 80/4885CHRNB4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.